Sign in →

Test Code FPAN2 Pancreastatin, Plasma


Shipping Instructions


Ship Frozen



Specimen Required


Patient Preparation:

1. Patient should not be on any medications that may influence Insulin levels, if possible, for at least 48 hours prior to collection.

2. Patient should be fasting 10 hours prior to collection. Patient may drink plain water; no other liquid is acceptable.

Specimen Type: Plasma

Collection Container/Tube: Z tube (MCL T701)

Submission Container/Tube: Plastic vial

Specimen Volume: 3 mL

Collection Instructions:

1. Draw 10 mL of blood in special Z-tube, pre-chilled (MCL T701).

2. Separate plasma from cells immediately after draw and freeze immediately after separation.

3. Send 3 mL of plasma frozen in a plastic vial.


Secondary ID

75907

Method Name

Direct Radioimmunoassay

Reporting Name

Pancreastatin, Plasma

Specimen Type

Z-Tube Plasma

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Z-Tube Plasma Frozen 60 days

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject
Specimens other than collected in Z tube (MCL T701). Reject

Clinical Information

Pancreastatin is a 49 amino acid peptide produced by degradation of Chromo-granin A. It inhibits Chromogranin A and Parathyroid Hormone release. Pancreastatin also inhibits release of Somatostatin upon glucose stimulation. It may also control carbohydrate metabolism and hyperglycemia. Although there are no compounds with significant structural homology with Pancreastatin, there are minor similarities to Gastrin and Anti-Diuretic Hormone. Pancreastatin reduces the early phase of Glucose induced Insulin release.  Suppression of Insulin release upon Glucose stimulation is a characteristic feature of Type II Diabetes. Pancreastatin could play an important therapeutic role in the treatment of diabetes. Pancreastatin also inhibits release of Somatostatin. It may also control carbohydrate metabolism and hyperglycemia.

Reference Values

10-135 pg/mL

Clinical Reference

1. Raines D, Chester M, Diebold AE, et al. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas. 2012;41(4):508-511

2. O'Dorisio TM, Krutzik SR, Woltering EA, et al. Development of a highly sensitive and specific carboxy-terminal human Pancreastatin assay to monitor neuroendocrine tumor behavior. Pancreas. 201;39(5):611-616

3. Piero E, Mirelles P, Silvestre RA, et al. Pancreastatin inhibits insulin secretion as induced by glucagon, vasoactive intestinal polypeptide, gastric inhibiting peptide, and 8-cholecystokinin in the perfused rat pancreas. Metabolism. 1989;38(7):679-682

4. Tatemoto K, Efendic S, Mutt S, et al. Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature. 1986;324(6096):476-478

5. Calhoun K, Toth-Fejel S, Chee J, et al. Serum peptide profiles in patients with carcinoid tumors. Am J Surg. 2003;186(1):28-31

6. Syverson U, Jacobsen MB, O'Connor DT, et al. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides. 1994;26(3):201-206

7. Kogner P, Bjellerup P, Svensson T, et al. Pancreastatin immunoreactivity in favourable childhood neuroblastoma and ganglioneuroma. Eur J Cancer. 1995;31A(4):557-560

8. Desai DC, O'Dorisio TM, Schirmer WJ, et al. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analog therapy in metastatic neuroendocrine tumors. Regul Pept. 2001;96(3):113-117

Day(s) Performed

Monday through Friday

Report Available

5 to 9 days

Performing Laboratory

Inter Science Institute

Test Classification

This test was developed and its characteristics determined by Inter Science Institute. Values obtained with different methods, laboratories, or kits cannot be used interchangeably with the results on this report. The results cannot be interpreted as absolute evidence of the presences or absence of malignant disease.

CPT Code Information

83519

LOINC Code Information

Test ID Test Order Name Order LOINC Value
FPAN2 Pancreastatin, Plasma Not Provided

 

Result ID Test Result Name Result LOINC Value
FPAN2 Pancreastatin, Plasma 49013-6